For the ongoing 2014 Ebola virus outbreak, all viable options and technologies need to be evaluated as potential countermeasures to address this emerging biological threat. Novavax, Inc. has a rapid, practical vaccine development and manufacturing platform with the capability to deliver clinical trial material and, ultimately, commercial doses in response to novel infectious disease agents. This report describes the application of our platform technology for the successful generation, manufacture, and release of a clinical batch of Zaire ebolavirus glycoprotein nanoparticle vaccine three months from project initiation…
Tag: <span>glycoprotein</span>
The baculovirus-insect cell system consists of a recombinant baculovirus vector and its host, which may be a lepidopteran insect larvae or an established lepidopteran insect cell line. Hundreds of different recombinant proteins have been produced using the baculovirus-insect cell system, facilitating biomedical research on protein structure, function, and the roles of various proteins in disease. In addition, many biotechnology companies are using this system to produce recombinant proteins for potential clinical use as vaccines, therapeutics, or diagnostic reagents…